InnoStar Bio-Tech

Shanghai InnoStar Bio-Tech Co., Ltd. was established in 2010 and is a holding subsidiary of China State Institute of Pharmaceutical Industry Co., Ltd. under Sinopharm Group. Adhering to the core values of "Science-led, Quality First, Integrity and Dedication, Win-win Cooperation", and promoting development through innovation, surviving by quality, winning customers with reputation, and creating benefits through management, InnoStar has successively passed NMPA GLP certification, US FDA GLP inspection, GLP certification from the Dutch government (an OECD member), AAALAC certification, and CAP certification from the College of American Pathologists. It is a professional comprehensive R&D service (CRO) enterprise focusing on nonclinical research services for biomedical products. Its business scope covers early druggability evaluation, nonclinical pharmacodynamics research, nonclinical pharmacokinetics research, nonclinical safety evaluation, clinical biosample analysis, biomarkers and translational research, and other fields.
After years of development, InnoStar now has nearly 60,000 square meters of modern facilities and a research team of over a thousand people, distributed in Shanghai, Nantong, Shenzhen, Huangshan, and other places. The company possesses advanced international service capabilities, aligns with international standards, and provides comprehensive one-stop new drug R&D services that meet domestic and international filing standards for global pharmaceutical companies and research institutions. As of December 31, 2022, it has completed more than 10,000 clinical and nonclinical evaluation project studies for over 640 pharmaceutical companies, new drug R&D institutions, and research institutes at home and abroad, contributing to 14 successful NDA cases for domestic innovative drug R&D, over 270 successful IND registration cases, and assisting more than 60 projects in obtaining regulatory filings from foreign agencies such as the US, EU, South Korea, and Australia.
InnoStar is committed to providing one-stop service solutions for domestic and international clients, continuously striving toward the corporate vision of "Pioneer in scientific innovation, Accelerator for new drug R&D, Guardian of life and health."